-
Product Insights
![]()
Net Present Value Model: Tovorafenib
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Tovorafenib Drug Details Tovorafenib (TAK-580 (MLN2480))...
-
Product Insights
![]()
Net Present Value Model: BGB-3245
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model BGB-3245 Drug Details BGB-3245 is under...
-
Product Insights
![]()
Net Present Value Model: VS-6766
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model VS-6766 Drug Details CKI-27 (RG-7304, RO5126766)...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07284892
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PF-07284892 Drug Details PF-07284892 is under development for the treatment of ALK- or ROS1-positive...
-
Product Insights
![]()
Net Present Value Model: KIN-002787
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model KIN-002787 Drug Details KIN-002787 is under...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – KIN-002787
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry KIN-002787 Drug Details KIN-002787 is under development for the treatment of solid tumors, non-small...
-
Product Insights
![]()
Net Present Value Model: lifirafenib maleate
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model lifirafenib maleate Drug Details Lifirafenib maleate...
-
Product Insights
![]()
Net Present Value Model: Naporafenibum
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Naporafenibum Drug Details Naporafenibum (LXH-254) is...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – DCC-3116
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry DCC-3116 Drug Details DCC-3116 is under development for the treatment of mutated RAS and...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABM-1310
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ABM-1310 Drug Details ABM-1310 is under development for the treatment of melanoma, colorectal cancer,...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – (MG-010 + sorafenib)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (MG-010 + sorafenib) Drug Details A fixed dose combination (MGD-1609) of MG-010 and sorafenib...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGB-3245
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BGB-3245 Drug Details BGB-3245 is under development for the treatment of solid tumors including...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – donafenib tosylate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry donafenib tosylate Drug Details Donafenib tosylate (Zepsun) is a deuterated sorafenib derivative. It is...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – lifirafenib maleate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry lifirafenib maleate Drug Details Lifirafenib maleate is under development for the treatment of solid...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – belvarafenib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry belvarafenib Drug Details Belvarafenib is under development for the treatment of solid tumor including...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – naporafenibum
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry naporafenibum Drug Details Naporafenibum (LXH-254) is under development for the treatment of advanced solid...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – VS-6766
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VS-6766 Drug Details CKI-27 (RG-7304, RO5126766) is under development for the treatment of solid...
-
Product Insights
![]()
Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Thyroid Cancer Pipeline Drugs Market Report Overview Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include a lump that can be felt through the skin on the neck, difficulty swallowing, pain in the neck and throat, and swollen lymph nodes in the neck. Predisposing factors include females, high levels of radiation, and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy. The Thyroid Cancer pipeline market report provides a comprehensive overview of the therapeutics under...
-
Product Insights
![]()
Serine-Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.